These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

922 related articles for article (PubMed ID: 15231022)

  • 1. RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1.
    Sankar U; Patel K; Rosol TJ; Ostrowski MC
    J Bone Miner Res; 2004 Aug; 19(8):1339-48. PubMed ID: 15231022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.
    Kobayashi K; Takahashi N; Jimi E; Udagawa N; Takami M; Kotake S; Nakagawa N; Kinosaki M; Yamaguchi K; Shima N; Yasuda H; Morinaga T; Higashio K; Martin TJ; Suda T
    J Exp Med; 2000 Jan; 191(2):275-86. PubMed ID: 10637272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation.
    Lee SE; Woo KM; Kim SY; Kim HM; Kwack K; Lee ZH; Kim HH
    Bone; 2002 Jan; 30(1):71-7. PubMed ID: 11792567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoclast differentiation is associated with transient upregulation of cyclin-dependent kinase inhibitors p21(WAF1/CIP1) and p27(KIP1).
    Okahashi N; Murase Y; Koseki T; Sato T; Yamato K; Nishihara T
    J Cell Biochem; 2001; 80(3):339-45. PubMed ID: 11135363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro differentiation of CD14 cells from osteopetrotic subjects: contrasting phenotypes with TCIRG1, CLCN7, and attachment defects.
    Blair HC; Borysenko CW; Villa A; Schlesinger PH; Kalla SE; Yaroslavskiy BB; Garćia-Palacios V; Oakley JI; Orchard PJ
    J Bone Miner Res; 2004 Aug; 19(8):1329-38. PubMed ID: 15231021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population.
    Nagata N; Kitaura H; Yoshida N; Nakayama K
    Bone; 2003 Oct; 33(4):721-32. PubMed ID: 14555278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha.
    Chaisson ML; Branstetter DG; Derry JM; Armstrong AP; Tometsko ME; Takeda K; Akira S; Dougall WC
    J Biol Chem; 2004 Dec; 279(52):54841-8. PubMed ID: 15485831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P; Tu Q; Chen J
    J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited rescue of osteoclast-poor osteopetrosis after successful engraftment by cord blood from an unrelated donor.
    Nicholls BM; Bredius RG; Hamdy NA; Gerritsen EJ; Lankester AC; Hogendoorn PC; Nesbitt SA; Horton MA; Flanagan AM
    J Bone Miner Res; 2005 Dec; 20(12):2264-70. PubMed ID: 16294279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoclast differentiation by RANKL requires NF-kappaB-mediated downregulation of cyclin-dependent kinase 6 (Cdk6).
    Ogasawara T; Katagiri M; Yamamoto A; Hoshi K; Takato T; Nakamura K; Tanaka S; Okayama H; Kawaguchi H
    J Bone Miner Res; 2004 Jul; 19(7):1128-36. PubMed ID: 15176996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
    Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
    J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin (IL)-12 mediates the anti-osteoclastogenic activity of CpG-oligodeoxynucleotides.
    Amcheslavsky A; Bar-Shavit Z
    J Cell Physiol; 2006 Apr; 207(1):244-50. PubMed ID: 16402377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells.
    Yang CR; Wang JH; Hsieh SL; Wang SM; Hsu TL; Lin WW
    Cell Death Differ; 2004 Jul; 11 Suppl 1():S97-107. PubMed ID: 15002040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
    Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M
    Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease status in autosomal dominant osteopetrosis type 2 is determined by osteoclastic properties.
    Chu K; Snyder R; Econs MJ
    J Bone Miner Res; 2006 Jul; 21(7):1089-97. PubMed ID: 16813529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct stimulation of osteoclastogenesis by MIP-1alpha: evidence obtained from studies using RAW264 cell clone highly responsive to RANKL.
    Watanabe T; Kukita T; Kukita A; Wada N; Toh K; Nagata K; Nomiyama H; Iijima T
    J Endocrinol; 2004 Jan; 180(1):193-201. PubMed ID: 14709158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the phytoestrogen coumestrol on RANK-ligand-induced differentiation of osteoclasts.
    Kanno S; Hirano S; Kayama F
    Toxicology; 2004 Oct; 203(1-3):211-20. PubMed ID: 15363596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors.
    Zauli G; Rimondi E; Stea S; Baruffaldi F; Stebel M; Zerbinati C; Corallini F; Secchiero P
    J Cell Physiol; 2008 Jan; 214(1):117-25. PubMed ID: 17620297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
    Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
    Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.